COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID
申请人:CaaMTech, LLC
公开号:US20190142851A1
公开(公告)日:2019-05-16
This disclosure pertains to new compositions and methods comprising a psilocybin derivative. In one embodiment, the compositions disclosed herein are used for a method of regulating a neurotransmitter receptor, e.g., a serotonin receptor. In one embodiment, the compositions disclosed herein comprise purified compounds, e.g., a purified psilocybin derivative, a purified cannabinoid, or purified terpene.
COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND
申请人:CAAMTECH, INC.
公开号:US20210346346A1
公开(公告)日:2021-11-11
Disclosed herein are compositions comprising a serotonergic tryptamine compound, combinations thereof, and methods of using them for treating and preventing a variety of human conditions. In one embodiment, disclosed herein are new compositions and methods which comprise a therapeutically effective amount of a first purified psilocybin derivative and a therapeutically effective amount of a second compound. The second compound is selected from the group consisting of a second purified psilocybin derivative, a purified terpene, a serotonergic drug, an adrenergic drug, a dopaminergic drug, a purified erinacine, and a purified hericenone.
[EN] NOVEL ERGOLINES AND METHODS OF TREATING MOOD DISORDERS<br/>[FR] NOUVELLES ERGOLINES ET PROCÉDÉS DE TRAITEMENT DE TROUBLES DE L'HUMEUR
申请人:[en]GILGAMESH PHARMACEUTICALS, INC.
公开号:WO2022226408A1
公开(公告)日:2022-10-27
The present disclosure provides ergoline compounds and their use in treating mood disorders. Pharmaceutical compositions and methods of making various ergoline compounds are provided.
Stereoselective LSD-like Activity in a Series of d-Lysergic Acid Amides of (R)- and (S)-2-Aminoalkanes
作者:Aaron P. Monte、Danuta Marona-Lewicka、Arthi Kanthasamy、Elaine Sanders-Bush、David E. Nichols
DOI:10.1021/jm00006a015
日期:1995.3
In rats trained to discriminate 0.08 mg/kg LSD tartrate from saline, a similar stereoselective effect was noted in which the (R)-alkylamides were more potent than the (S)-isomers in producing the LSD-like discriminative stimulus effect. However, as the amide alkyl substituent was increased in length, LSD-like activity decreased, with only partial substitution for training drug being observed for the
合成了d-麦角酸的3-戊基,(R)-和(S)-2-戊基,2-己基和2-庚基酰胺,并在生化和行为分析中评估了类似LSD的活性。在放射性配体竞争研究中,从大鼠皮质匀浆中的5-HT2A受体置换[3H]酮色林和[3H] -8-OH-DPAT置换中,(R)-麦角酰脲始终比(S)-酰胺更有效(大鼠海马5-HT1A受体的[3H] -8-羟基-2-(二正丙基氨基)四氢萘)。随着酰胺烷基从戊基延长到庚基,(R)异构体对5-HT2A位点的亲和力降低,而对5-HT1A位点的亲和力对于(R)-2-己基麦角酰胺最大。在训练中可从盐水中区分出0.08 mg / kg LSD酒石酸的大鼠中,注意到相似的立体选择性作用,其中(R)-烷基酰胺比(S)-异构体在产生类似LSD的判别性刺激作用中更有效。然而,随着酰胺烷基取代基长度的增加,LSD样活性降低,仅观察到(R)-己酰胺部分取代了训练药物。还测定了(R)-和(S)-戊基